Concepedia

Author

Piercarla Schinco

Azienda Ospedaliero Universitaria San Giovanni Battista

Also Known As

M. Morfini, P C Schinco, P Schinco, P. C. SCHINCO, P. C. Schinco, P. SCHINCO, P. Schinco, P.C. Schinco, PierCarla Schinco, Piercarla Schinco

62

Publications

2.2K

Citations

18

H-Index

47

Concepts

All Affiliations

Azienda Ospedaliero Universitaria San Giovanni BattistaFondazione Ricerca MolinetteUniversity of TurinSapienza University of RomeUniversity of Parma
PS

About

Piercarla Schinco is an author at Azienda Ospedaliero Universitaria San Giovanni Battista specializing in medicine, hematology, and thrombosis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

12

1.4K

2

Health Sciences

5

5

594

3

Anesthesia

1

1

13

4

Biochemistry

1

1

15

5

Cell Biology

1

1

13

Piercarla Schinco

×

22

Publications

2K

Citations

17

H-Index

YearCitations

A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

Guido Finazzi, Roberto Marchioli, Vincenzo Brancaccio,

Journal of Thrombosis and Haemostasis

2005

582

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registry

Guido Finazzi, Vincenzo Brancaccio, Marco Moia,

The American Journal of Medicine

1996

435

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A

Corien L. Eckhardt, Alice S. van Velzen, Marjolein Peters,

Blood

2013

214

Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia

M. Bazzan, G. Tamponi, Piercarla Schinco,

Annals of Hematology

1999

111

Studies on Mechanisms Involved in Hypoglycemia-Induced Platelet Activation

Mariella Trovati, Giovanni Anfossi, Franco Cavalot,

Diabetes

1986

77

Clinical efficacy of highly purified, doubly virus‐inactivated factor VIII/von Willebrand factor concentrate (Fanhdi<sup>®</sup>) in the treatment of von Willebrand disease: a retrospective clinical study

Augusto B. Federici, F. Baudo, Clementina Caracciolo,

Haemophilia

2002

62

A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice

Simone Merlin, Elvira Stefania Cannizzo, Ester Borroni,

Molecular Therapy

2017

61

A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs

Elena Crisà, Ermanno Venturino, Roberto Passera,

Annals of Hematology

2010

59

Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A

Cristina Olgasi, Maria Talmon, Simone Merlin,

Stem Cell Reports

2018

59

A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Flora Peyvandi, Giancarlo Castaman, Paolo Gresele,

PubMed

2019

44

Page 1